Terminal Disclaimer To Obviate A Double						Docket No.			
Patenting Rejection Over A Prior Patent						Army140D			
In Re Application Of: Ulrich et al.									
Application No.	Filing	Date \	2	Examiner		Customer No.	Group Art Unit	Confirmation No.	
10/767,687	January	29, 2004	A Allen	Parianne P.			1647	8007	
Invention: BACTERIAL SUPERANTIGEN VACCINES									
		· •							
		i i							
Owner of Record: United States Army Medical Research Institute of Infectious Diseases									
Owner of Record. United States Army Medical Research Institute of Infectious 2.55-6-6-6									
		:							
		•							
COMMISSIONER FOR PATENTS:									
The above-identified owner of record of a 100 percent interest in the instant application hereby disclaims, except as									
provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6.713,284 The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.									
Check either box 1 or 2 below, if appropriate.									
1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.									
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.									
2. The undersigned is an attorney of record.									
Elizabeth Armine Dated: 11 December 2007									
ELIZABETH ARWINE									
Typed or Printed Name Terminal disclaimer fee under 37 C.F.R. 1.20(d) included.									
PTO suggested wording for terminal disclaimer was unchanged. Certification under 37 C.F.R. 3.73(b) is required if terminal disclaimer is signed by the assignee.									

PTO/SB/96 (04-07)

Approved for use through 09/30/2007, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

TRADEWATEMENT UNDER 37 CFR 3.73(b)

DEC 2 8 7,007

Applicant/Patent Owner: United States Army Medical Research Institute	e of Infectious Diseases (USAMRIID)
Application No./Patent No.: 6,713,284	Filed/Issue Date: March 30, 2004
Entitled: Bacterial Superantigen Vaccines	
USAMRIID , a Government ag	gency
(Name of Assignee) (Type of Assignee, e.g., or	orporation, partnorship, university, government sgency, etc.)
states that it is:	
1. the assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is	%)
in the patent application/patent identified above by virtue of either:	
A. An assignment from the Inventor(s) of the patent application/patent Identified States Patent and Trademark Office at Reel012246, Frame	d above. The assignment was recorded in the United 0605 , or for which a copy thereof is attatched.
OR	
B. A chain of title from the inventor(s), of the patent application/patent identified	d above, to the current assignee as follows:
From: To: To: The document was recorded in the United States Patent and Trademark Office Reel, or for which a copy the, or for which a copy the	æ at
—	
2. From: To: The document was recorded in the United States Patent and Trademark Office	
Reel, Frame, or for which a copy the	ereof is attached.
3. From: To:	
The document was recorded in the United States Patent and Trademark Office Reel, or for which a copy the	ce at ereof is attached.
Additional documents in the chain of title are listed on a supplemental shee	et.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document accordance with 37 CFR Part 3, to record the assignment in the record	(s)) must be submitted to Assignment Division in
The undersigned (whose title is supplied below) is authorized to act on behalf of the a	
Elizabeth Armine Signature	11 December, 2007
Elizabeth Arwine	301-619-7808 Telephone number
Printed or Typed Name	releptione number
Attorney for applicant	_
; Title	

This collection of Information is required by 37 CFR 3.73(b). The information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to process) an application. Confidentiatify is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.